Prediction and Analysis of Epitopes in clpP2 of Mycobacterium tuberculosis

LIU Si-jing, JIANG Ming-juan, PU Qi-kang. et al

Abstract

To predict and analyze the antigenic epitopes in Mycobacterium tuberculosis protein caseinolytic protease P2 (clpP2), and explore its possibility to be applied as a new tuberculosis (TB) vaccine and drug development target. Methods Secondary structure of clpP2 based on nucleic sequence was predicted by DNA Star software. The homologous sequence conformation were analyzed by Swiss-Model online software. T cells antigenic epitopes were predicted through VaxiPred, and B cell epitopes were predicted by combining use of several different prediction programs, such as ABCpred, COBEPro and BepiPredPred. The immune characteristics of clpP2 were analyzed by DNA Star, SignalP, TMHMM online software and were searched through NCBI database. Results clpP2protein was diverse in structure, composing with a great deal of CTL and Th cell epitopes. clpP2 was also predicted to comprise rich potential liner and discontinuous B-cell epitopes. These epitopes were accessible on the protein surface, located in flexible and hydrophilic regions. Conclusion clpP2 is prompted to induce immune responses and developes a novel target in surveillance, treatment and vaccine.

 

Keywords: Mycobacterium tuberculosis clpP2, Epitope 

 

Full Text:

PDF


References


World Health Organisation. Global tuberculosis report 2015 [2015-10-22]. http://www.who. int /tb/publications/Global _report/en/.

World Health Organisation. Guidelines on the Management of Latent Tuberculosis Infection [ 2015-10-22 ]. http;//www. who. int/tb/publications/latent-tuberculosis-infection/en.

PERSONNE Y, BROWN AC. SCHUESSLER DL,et al. Mycobacterium tuberculosis ClpP proteases are cotranscribed but exhibit different substrate specificities. PloS One. 2013. 8 (4 ) : e60228 [2015-01-19]. http;//www. ncbi. nlm. nih. gov/ pmc/articles/PMC3613350/. doi; 10. 1371/journal, pone.

BIASINI M. BIENERT S, WATERHOUSE A, et al. SWISS-MODEL; modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res, 2014, 42 (Web Server issue ) : W252-W258 [ 2015-01-19 ]. http;//www. ncbi. nlm. nih. gov/pmc/articles/PMC 4086089/. doi: 10. 1093/nar/gku340.

ARNOLD K, BORDOLI L, KOPP J, et al. The SWISS- MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics, 2006 , 22 ( 2) ; 195-201.

BENKERT P, BIASINI M, SCHWEDE T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics,2011,27(3) ;343-350.

BISHAI W. SULLIVAN Z, BLOOM BR. et al. Bettering BCG: a tough task for a ТВ vaccine? Nat Med,2013,19(4) ; 410-411.

NARAYANAN PR. Influence of sex. age &- nontuberculous infection at intake on the efficacy of BCG: reanalysis of 15 year data from a double-blind randomized control trial in south India. Indian J Med Res,2006,123(2): 119-124.

PETRIZZD A, TORNESELLO M. BUONAGURO FM, et al. Immunogenomics approaches for vaccine evaluation. J Immunotoxicol,2012,9(3);236-240.

LIU EB, WADFORD DA, SETO J. et al. Computational and serologic analysis of novel and known viruses in species human adenovirus D in which serology and genomics do not correlate. PloS One,2012,7( 3): e33212[2015-01-19], http; //www. ncbi. nlm. nib. gov/pmc/articles/PMC3302849/. doi: 10. 1371/journal, pone. 0033212.Rev,2014,40(6):730-738.

ZHAU HE. LI CL. CHUNG LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer.2000, 88(12 Suppl) :2995-3001.

ROSOL TJ. TANNEHILL-GREGG SH, LEROY BE, et al. Animal models of bone metastasis. Cancer. 2003. 97 ( 3 Suppl);748-757.

VIGNANI F, BERTAGLIA V. BUTTIGLIERO C, et al. Skeletal metastases and impact of anticancer and bone- targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev, 2016 ( 44 ): 61-73 [2015-06-13]. http://www. sciencedirect. com,/ science/article/pii,/S030 5737216000177. doi; 10. 1016/j. ctrv. 2016. 02. 002.

KUPERWASSER C, DESSAIN S, BIER BAUM BE, et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res,2005,65(14);6130-6138.

ANGELUCCI A, GRAVINA GL, RUCCI N, et al. Evaluation of metastatic potential in prostate carcinoma; an in vivo model. Int J Oncol,2004 ,25( 6): 1713-1720.

FISHER JL, SCHMITT JF, HOWARD ML, et al. An in vivo model of prostate carcinoma growth and invasion in bone. Cell Tissue Res,2002,307(3) ;337-345.

BALAJI КС, HURYK RF, VERHULST S, et al. Growth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium. Prostate, 2001, 48 ( 4 ); 265- 273.

HRICAKH. CHOYKE PL. EBERHARDT SC, et al.Imaging prostate cancer; a multidisciplinary perspective. Radiology,2007,243( 1):28-53.

LECOUVET FE. LHOMMEL R. PASOGLOU V, et al. Novel imaging techniques reshape the landscape in high-risk prostate cancers. Curr Opin Urol,2013,23(4):323-330.

FRADET A, SOREL H, DEPALLE B, et al. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One, 2013, 8 ( 9 ): e75092[2016-02-02]. http;//dx. doi.org/10.1371/journal. pone. 0075092.

OYEN WJ, WITJESJA, CORSTENS FH. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur Urol,2001,40(3);294-299.

BLAKE GM, PARK-HOLOHAN SJ, COOK GJ, et al. Quantitative studies of bone with the use of uF-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001, 31 (1) : 28-49.

LANGSTEGER W. HEINISCH M, FOGELMAN I. The role of fluorodeoxyglucose, 18 F-dihydroxyphenylalanine, lsF- choline, and I8F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med.2006,36(1);73-92.

GRECCHI E, O’DOHERTY J, VERONESE M, et al. Multimodal partial-volume correction; application to 18F- fluoride PET/CT bone metastases studies. J Nucl Med, 2015,56(9):1408-1414.


Refbacks

  • There are currently no refbacks.